Symphogen is a clinical-stage antibody oncology-focused company leading the field of recombinant antibody mixtures for therapeutic use. It is our vision to develop superior mAb therapeutics to improve the lives of patients with significant unmet medical needs.

Our pipeline of differentiated and novel monoclonal antibody, or mAb, mixture products is uniquely designed to address tumor diversity and resistance by combining multiple antibodies in a single drug product while addressing today's need for precision medicine.

We think in "symphonies" of antibodies. Much as a symphony requires the sounds of multiple instruments to achieve a symphonic impression, Symphogen begins with the notion that only a multi-factorial approach can achieve solutions that mimic the successful mechanisms Mother Nature has brought to bear to fight disease.  From the conception of a project idea to the generation of a mAb mixture product ready to enter human clinical trials, we strive to understand the multiple biological challenges of a disease and to carefully select and optimize just the optimal mAb mixture product for complex therapeutic situations.

Symphogen A/S
Pederstrupvej 93
DK-2750 Ballerup
Tel +45 4526 5050
Fax +45 4526 5060

Investor Inquiries
Martin Olin, CEO

Business Development Inquiries
Jette Asboe Lassen, VP

Media Inquiries
Heidi K. Roennest
Executive Office Manager